Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. This engagement provides a platform for Helus Pharma to showcase its innovative pipeline, which targets large unmet needs in mental health treatment.
The company’s proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Among its lead candidates, HLP003 is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation underscores the potential of HLP003 to offer a significant improvement over existing therapies. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs are part of a broader research portfolio that includes several investigational NSAs.
The implications of Helus Pharma’s participation in the Jefferies conference are significant. It offers investors and industry stakeholders a closer look at the company’s progress and strategic direction. The webcast and replay availability ensure broad access to the discussion, which could influence market perception and investor confidence. Moreover, the conference provides a venue for Helus Pharma to network with potential partners and collaborators, potentially accelerating its development timelines.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape for depression, anxiety, and other mental health conditions through its proprietary NSAs. With class-leading data, Helus Pharma seeks to provide durable improvements in mental health, addressing a critical gap in current therapeutic options.
For more details on the announcement, the full press release is available at https://ibn.fm/1QdP7. Investors can also access the latest news and updates on the company’s newsroom at https://ibn.fm/HELP.
